Search
LX6171
go.drugbank.com/drugs/DB05180InvestigationalLX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia
Pipendoxifene
go.drugbank.com/drugs/DB05414InvestigationalER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. … Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment
Denatonium
go.drugbank.com/drugs/DB18588InvestigationalSynonyms: Benzenemethanaminium, n-(2-((2,6-dimethylphenyl)amino)-2-oxoethyl)-n,n-diethylCategories: Compounds used in a research, industrial, or household settingMimosine
go.drugbank.com/drugs/DB01055ExperimentalMimosine is an antineoplastic alanine-substituted pyridine derivative isolated from _Leucena glauca_.
Bisegliptin
go.drugbank.com/drugs/DB06127InvestigationalIt is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion
HGTV-43
go.drugbank.com/drugs/DB05807ExperimentalHGTV43 is an anti-sense treatment designed to produce T cells that are genetically resistant to HIV infection.
Dialyzable leukocyte extract
go.drugbank.com/drugs/DB16530InvestigationalIt is thought to have widespread effects on the immune system, and effective in treating infections and immunological issues. … Transferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator.
LX1031
go.drugbank.com/drugs/DB05199InvestigationalLX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system … LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders.
GPI-0100
go.drugbank.com/drugs/DB05929InvestigationalThe GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy